Verve Therapeutics Long Term Debt

Verve Therapeutics (VERV) currently reports a long-term debt of $58M as of March 2025. That compares with $63M in the prior-year period — down 8.4% year over year. Use the charts on this page to explore Verve Therapeutics's long-term debt history and peer comparisons.

Verve Therapeutics's long-term debt decreased from $63M to $58M — a 8.4% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Verve Therapeutics reported $58M in long-term debt as of March 2025. That compares with $63M in the prior-year period — down 8.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $58M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Verve Therapeutics, and consider following VERV for alerts when major investors trade the stock.

Verve Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $58M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VERV with unrelated industries.